El estudio CRASH-2 ya dejaba ver un camino para el politrauma grave parece que se suman nuevos datos... A ver si la nueva revisión del ATLS/PHTLS lo recoge... RESEARCH Effect of tranexamic acid on mortality in patients with traumatic bleeding: prespecified analysis of data from randomised controlled trial BMJ 2012; 345 doi: 10.1136/bmj.e5839 (Published 11 September 2012) Cite this as: BMJ 2012;345:e5839 Clinical trials (epidemiology) Epidemiologic studies Article Related content Article metrics Ian Roberts, professor1, Pablo Perel, senior clinical lecturer1, David Prieto-Merino, lecturer, medical statistics1, Haleema Shakur, senior lecturer in clinical trials1, Tim Coats, professor2, Beverley J Hunt, professor3, Fiona Lecky, professor4, Karim Brohi, professor5, Keith Willett, professor6 on behalf of the CRASH-2 collaborators. Author Affiliations Correspondence to: I Roberts firstname.lastname@example.org Accepted 18 August 2012 Abstract Objectives To examine whether the effect of tranexamic acid on the risk of death and thrombotic events in patients with traumatic bleeding varies according to baseline risk of death. To assess the extent to which current protocols for treatment with tranexamic acid maximise benefits to patients. Design Prespecified stratified analysis of data from an international multicentre randomised controlled trial (the CRASH-2 trial) with an estimation of the proportion of premature deaths that could potentially be averted through the administration of tranexamic acid. Participants 13 273 trauma patients in the CRASH-2 trial who were treated with tranexamic acid or placebo within three hours of injury and trauma patients enrolled in UK Trauma and Audit Research Network, stratified by risk of death at baseline (<6%, 6-20%, 21-50%, >50%). Intervention Tranexamic acid (1 g over 10 minutes followed by 1 g over eight hours) or matching placebo. Main outcome measure Odds ratios and 95% confidence intervals for death in hospital within four weeks of injury, deaths from bleeding, and fatal and non-fatal thrombotic events associated with the use of tranexamic acid according to baseline risk of death. Unless there was strong evidence against the null hypothesis of homogeneity of effects (P<0.001), the overall odds ratio was used as the most reliable guide to the odds ratios in all strata. Results Tranexamic acid was associated with a significant reduction in all cause mortality and deaths from bleeding. In each stratum of baseline risk, there were fewer deaths among patients treated with tranexamic acid. There was no evidence of heterogeneity in the effect of tranexamic acid on all cause mortality (P=0.96 for interaction) or deaths from bleeding (P=0.98 by baseline risk of death. In those treated with tranexamic acid there was a significant reduction in the odds of fatal and non-fatal thrombotic events (odds ratio 0.69, 95% confidence interval 0.53 to 0.89; P=0.005) and a significant reduction in arterial thrombotic events (0.58, 0.40 to 0.83; P=0.003) but no significant reduction in venous thrombotic events (0.83, 0.59 to 1.17; P=0.295). There was no evidence of heterogeneity in the effect of tranexamic acid on the risk of thrombotic events (P=0.74). If the effect of tranexamic acid is assumed to be the same in all risk strata (<6%, 6-20%, 21-50%, >50% risk of death at baseline), the percentage of deaths that could be averted by administration of tranexamic acid within three hours of injury in each group is 17%, 36%, 30%, and 17%, respectively. Conclusions Tranexamic acid can be administered safely to a wide spectrum of patients with traumatic bleeding and should not be restricted to the most severely injured.